LU91362I2 - Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA) - Google Patents
Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)Info
- Publication number
- LU91362I2 LU91362I2 LU91362C LU91362C LU91362I2 LU 91362 I2 LU91362 I2 LU 91362I2 LU 91362 C LU91362 C LU 91362C LU 91362 C LU91362 C LU 91362C LU 91362 I2 LU91362 I2 LU 91362I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- pharmaceutically acceptable
- invega
- paliperidone
- compounds
- acceptable derivatives
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title 2
- 229940013946 invega Drugs 0.000 title 1
- 229960001057 paliperidone Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- FFESGTAUFAZQRI-UHFFFAOYSA-N 3-piperidin-1-yl-1,2-benzoxazole Chemical class C1CCCCN1C1=NOC2=CC=CC=C12 FFESGTAUFAZQRI-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26785788A | 1988-11-07 | 1988-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU91362I2 true LU91362I2 (fr) | 2007-11-12 |
Family
ID=23020416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU91362C LU91362I2 (fr) | 1988-11-07 | 2007-09-12 | Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA) |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0368388B1 (fr) |
| JP (1) | JP2758045B2 (fr) |
| KR (1) | KR0146053B1 (fr) |
| AT (1) | ATE122349T1 (fr) |
| AU (1) | AU614437B2 (fr) |
| CA (1) | CA2000786C (fr) |
| CL (1) | CL43432B (fr) |
| CY (2) | CY1926A (fr) |
| DE (2) | DE68922577T2 (fr) |
| DK (1) | DK169923B1 (fr) |
| ES (1) | ES2075036T3 (fr) |
| FI (1) | FI92201C (fr) |
| HK (1) | HK131696A (fr) |
| IE (1) | IE66370B1 (fr) |
| IL (1) | IL92208A0 (fr) |
| LU (1) | LU91362I2 (fr) |
| NL (1) | NL300298I2 (fr) |
| NO (2) | NO173015C (fr) |
| NZ (1) | NZ231062A (fr) |
| PT (1) | PT92206B (fr) |
| ZA (1) | ZA898436B (fr) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9008850D0 (en) * | 1990-04-19 | 1990-06-13 | Janssen Pharmaceutica Nv | Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones |
| JPH07502268A (ja) * | 1991-11-27 | 1995-03-09 | ノボ ノルディスク アクティーゼルスカブ | 化学化合物、それらの製法および使用 |
| US5378714A (en) * | 1991-11-27 | 1995-01-03 | Novo Nordisk A/S | Antipsychotic piperidine derivatives |
| ES2050069B1 (es) * | 1992-07-10 | 1994-12-16 | Vita Invest Sa | Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona. |
| DK60593D0 (da) * | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Kemiske forbindelser, deres fremstilling og anvendelse |
| DK60793D0 (da) * | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Kemiske forbindelser, deres fremstilling og anvendelse |
| RO119224B1 (ro) * | 1993-11-19 | 2004-06-30 | Janssenápharmaceuticaán.V. | Compoziţie farmaceutică pentru tratamentul unor afecţiuni psihotice şi utilizarea acesteia |
| ES2137486T3 (es) * | 1993-11-23 | 1999-12-16 | Janssen Pharmaceutica Nv | Derivados de 9-hidroxi-pirido(1,2-a)pirimidin-4-ona-eter. |
| ES2085234B1 (es) * | 1994-02-24 | 1997-01-16 | Vita Invest Sa | Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| TW487572B (en) * | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
| UA72189C2 (uk) * | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| ES2141671B1 (es) * | 1997-12-26 | 2001-01-01 | Vita Invest Sa | Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| US6500833B1 (en) | 1998-05-18 | 2002-12-31 | Sepracor Inc. | (+)-Hydroxyrisperidone compositions and methods |
| US6326362B1 (en) | 1998-05-18 | 2001-12-04 | Sepracor Inc. | (-)-phosphonorisperidone and (-)-sulforisperidone compositions and methods |
| WO2000010572A1 (fr) * | 1998-08-18 | 2000-03-02 | Sepracor Inc. | Utilisation de l'hydroxyrisperidone pour la fabrication d'un medicament destine au traitement et a la prevention des psychoses, des vomissements et des syndromes de sevrage a l'alcool et a la nicotine |
| ES2197801B1 (es) * | 2002-03-05 | 2005-03-16 | Ferrer Internacional,S.A | Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona. |
| KR20040025224A (ko) * | 2002-09-18 | 2004-03-24 | 주식회사 대웅 | 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법 |
| HRP20050424A2 (en) | 2002-11-13 | 2006-08-31 | Synthon B.V. | Process for making risperidone and intermediates thereof |
| EP1791839B1 (fr) | 2004-09-09 | 2015-06-10 | Janssen Pharmaceutica NV | PREPARATION DE 9-HYDROXY-3-(2-HYDROXYETHYL)-2-METHYL-4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE ET LEURS CRISTAUX |
| US20070197591A1 (en) | 2005-12-12 | 2007-08-23 | Sandra Boom | Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function |
| EP1940834A2 (fr) | 2006-08-14 | 2008-07-09 | Teva Pharmaceutical Industries Ltd. | Formes cristallines de la 9-hydroxy-rispéridone (palipéridone) |
| EP2133352A3 (fr) * | 2006-08-14 | 2010-01-13 | Teva Pharmaceutical Industries Ltd. | Forme cristalline de la 9-hydroxy-rispéridone (palipéridone) |
| EP2133351A3 (fr) * | 2006-08-14 | 2010-01-13 | Teva Pharmaceutical Industries Ltd. | Forme cristalline de la 9-hydroxy-rispéridone (palipéridone) |
| WO2008024415A2 (fr) * | 2006-08-23 | 2008-02-28 | Teva Pharmaceutical Insustries Ltd. | Procédé destiné à la synthèse de cmhtp et de ses intermédiaires |
| US7820816B2 (en) | 2006-08-23 | 2010-10-26 | Teva Pharmaceutical Industries Ltd. | Process for the synthesis of CMHTP and intermediates thereof |
| US8071767B2 (en) | 2007-01-08 | 2011-12-06 | Actavis Group Ptc Ehf | Process for preparation of 9-hydroxy-3-(2-chloroethyl)-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one hydrochloride |
| CN101641353B (zh) * | 2007-04-19 | 2012-05-23 | 长春健欣生物医药科技开发有限公司 | 用于治疗精神疾病的新颖化合物及其制备方法和用途 |
| WO2009010988A1 (fr) * | 2007-07-19 | 2009-01-22 | Natco Pharma Limited | Procédé amélioré, industriellement viable pour la préparation de palipéridone de haute pureté |
| WO2009015828A1 (fr) * | 2007-07-27 | 2009-02-05 | Synthon B.V. | Dérivés de palipéridone |
| WO2009045489A2 (fr) * | 2007-10-03 | 2009-04-09 | Teva Pharmaceutical Industries Ltd. | Procédé de synthèse de cmhtp, un intermédiaire de la palipéridone |
| EP2195318A2 (fr) | 2007-10-09 | 2010-06-16 | Cipla Limited | Procédés de préparation de palipéridone et de ses sels pharmaceutiquement acceptables et d'intermédiaires pour une utilisation dans les procédés |
| US7977480B2 (en) | 2007-12-10 | 2011-07-12 | Synthon Bv | Synthesis of paliperidone |
| WO2009116071A2 (fr) * | 2008-02-05 | 2009-09-24 | Watson Pharma Private Limited | Procédé amélioré pour la préparation de palipéridone |
| EP2285804A4 (fr) * | 2008-04-21 | 2011-09-14 | Glenmark Generics Ltd | Procédé pour la fabrication d'intermédiaires de palipéridone |
| US8309717B2 (en) | 2008-05-29 | 2012-11-13 | Inke, S.A. | Process to prepare paliperidone and intermediates thereof |
| EP2300467A4 (fr) | 2008-06-16 | 2012-04-25 | Msn Lab Ltd | Nouveaux procédés améliorés de préparation de la palipéridone |
| WO2010003702A1 (fr) * | 2008-07-11 | 2010-01-14 | Synthon B.V. | Synthèse de palipéridone |
| US7932385B2 (en) | 2008-07-11 | 2011-04-26 | Synthon Bv | Paliperidone ketone |
| SI22856A (sl) * | 2008-07-31 | 2010-02-26 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Proces za pripravo paliperidona |
| EP2161019A1 (fr) | 2008-09-05 | 2010-03-10 | KRKA, D.D., Novo Mesto | Composition pharmaceutique multi-particules à libération prolongée comportant de la palipéridone |
| EP2199293A1 (fr) | 2008-12-22 | 2010-06-23 | Chemo Ibérica, S.A. | Procédé à étape unique pour la préparation de palipéridone en son sel d'oxalate |
| EP2202234A1 (fr) | 2008-12-24 | 2010-06-30 | Laboratorios Lesvi, S.L. | Purification de la palipéridone |
| SI2275423T1 (sl) | 2009-07-13 | 2012-06-29 | Krka D.D., Novo Mesto | Postopek za sintezo paliperidona |
| WO2011018246A2 (fr) | 2009-08-13 | 2011-02-17 | Synthon B.V. | Composition de palipéridone à libération contrôlée |
| EP2343296A1 (fr) | 2009-12-01 | 2011-07-13 | Chemo Ibérica, S.A. | Procédé pour la purification de la palipéridone |
| WO2011074017A1 (fr) * | 2009-12-17 | 2011-06-23 | Alkem Laboratories Ltd. | Nouveau procédé de préparation de palipéridone |
| US8088594B2 (en) * | 2010-03-16 | 2012-01-03 | Saladax Biomedical Inc. | Risperidone immunoassay |
| WO2012035554A1 (fr) * | 2010-09-14 | 2012-03-22 | Megafine Pharma (P) Ltd. | Procédé amélioré de préparation de palipéridone très pure |
| WO2012068161A1 (fr) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive |
| CN102153552B (zh) * | 2011-03-01 | 2012-08-22 | 吉林大学 | 两种帕潘立酮药物共晶及其制备方法 |
| CN102206210B (zh) * | 2011-04-01 | 2014-07-02 | 常州市第四制药厂有限公司 | 一种6-氟-3-(4-哌啶基)-1，2-苯并异噁唑盐酸盐的生产方法 |
| EP3610890A1 (fr) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Procédés et compositions de traitement de la schizophrénie |
| EP3083569B1 (fr) | 2013-12-20 | 2022-01-26 | Agenebio, Inc. | Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive |
| CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11377445B2 (en) | 2018-02-21 | 2022-07-05 | Zenvision Pharma Llp | Derivatives of paliperidone and process for the preparation thereof |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP4572852A1 (fr) | 2022-08-19 | 2025-06-25 | Agenebio, Inc. | Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive |
| CN116003404B (zh) * | 2022-12-14 | 2024-10-01 | 杭州同舟生物技术有限公司 | 一种利培酮人工半抗原、人工抗原及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342870A (en) * | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
-
1989
- 1989-10-16 CA CA002000786A patent/CA2000786C/fr not_active Expired - Lifetime
- 1989-10-18 NZ NZ231062A patent/NZ231062A/xx unknown
- 1989-10-30 ES ES89202724T patent/ES2075036T3/es not_active Expired - Lifetime
- 1989-10-30 EP EP89202724A patent/EP0368388B1/fr not_active Expired - Lifetime
- 1989-10-30 CY CY192689A patent/CY1926A/xx unknown
- 1989-10-30 DE DE68922577T patent/DE68922577T2/de not_active Expired - Lifetime
- 1989-10-30 DE DE122007000081C patent/DE122007000081I2/de active Active
- 1989-10-30 AT AT89202724T patent/ATE122349T1/de active
- 1989-11-03 IL IL92208A patent/IL92208A0/xx not_active IP Right Cessation
- 1989-11-06 DK DK551989A patent/DK169923B1/da not_active IP Right Cessation
- 1989-11-06 PT PT92206A patent/PT92206B/pt not_active IP Right Cessation
- 1989-11-06 AU AU44436/89A patent/AU614437B2/en not_active Expired
- 1989-11-06 NO NO894411A patent/NO173015C/no not_active IP Right Cessation
- 1989-11-06 FI FI895261A patent/FI92201C/fi active Protection Beyond IP Right Term
- 1989-11-06 ZA ZA898436A patent/ZA898436B/xx unknown
- 1989-11-06 IE IE356489A patent/IE66370B1/en not_active IP Right Cessation
- 1989-11-07 JP JP1289842A patent/JP2758045B2/ja not_active Expired - Lifetime
- 1989-11-07 KR KR1019890016114A patent/KR0146053B1/ko not_active Expired - Lifetime
-
1996
- 1996-07-18 HK HK131696A patent/HK131696A/en not_active IP Right Cessation
-
2004
- 2004-05-20 CL CL200401183A patent/CL43432B/es active
-
2007
- 2007-09-12 LU LU91362C patent/LU91362I2/fr unknown
- 2007-10-15 CY CY200700025C patent/CY2007025I1/el unknown
- 2007-10-17 NL NL300298C patent/NL300298I2/nl unknown
- 2007-12-21 NO NO2007017C patent/NO2007017I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU91362I2 (fr) | Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA) | |
| EP0151824A3 (en) | N-(4-piperidinyl) bicyclic condesed 2-imidazolamine derivatives | |
| FI900085A0 (fi) | Menetelmä terapeuttisesti käyttökelpoisten N-(pyrimidin- ja kondensoitu pyrimidin-4-oni)etyyli-piperidiini- ja piperatsiinijohdannaisten valmistamiseksi | |
| NO176051C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperazinylbenzazol-derivater | |
| AU1810988A (en) | Novel n-(4-piperidinyl)bicyclic condensed 2-imidazolamine derivatives | |
| NO176608C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperidinylindazol-derivater |